slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
224,341-224,370 of 319,975
28
The slide uses a grid layout to display logos of various research and clinical partners.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a chevron-based timeline to distinguish between past achievements (checkmarks) and future goals (dots).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
30
This is the final slide of the deck.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
31
The chart shows a clear divergence between the treatment and placebo groups over time, with error bars indicating variability.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
32
The chart highlights a 13.3% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
33
The table includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various ALS functional domains.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
01
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Problem1 hit
02
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Problem1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a split layout: team members on the left and their associated track record (logos) on the right.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a timeline-based pipeline layout to show the progression of two drug candidates.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a detailed biological pathway diagram created with BioRender.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor growth inhibition by NXP800 compared to Cisplatin in both resistant and sensitive models.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient MRI, a schematic of the PDX study design, a line chart showing tumor volume over time, and photographic evidence of tumor size reduction.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Market Size1 hit
11
The slide presents preclinical efficacy data for NXP800 in specific genetic subtypes of endometrial cancer.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Market Size1 hit
12
Includes footnotes regarding NGS panels and weighted average calculations.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Market Size1 hit
13
The slide uses a split-column layout to contrast two phases of a clinical trial.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
16
The charts are kinome dendrograms (KinomeScan style).Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · CompetitionLoop · Quick Win Big Bet1 hit
17
The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · CompetitionLoop · Quick Win Big Bet1 hit
18
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
The charts show tumor regression in NXP900 treated groups versus tumor growth in control groups over 27 days.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
The slide uses a structured table to segment market opportunity by biological markers.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Financials1 hit
24
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit